



HAL
open science

Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations

Mansooreh Jaberipour, Simon O. Vass, Christopher P. Guise, Jane I. Grove, Richard J. Knox, Longqin Hu, Eva I. Hyde, Peter F. Searle

► To cite this version:

Mansooreh Jaberipour, Simon O. Vass, Christopher P. Guise, Jane I. Grove, Richard J. Knox, et al.. Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations. *Biochemical Pharmacology*, 2009, 79 (2), pp.102. 10.1016/j.bcp.2009.07.025 . hal-00535819

HAL Id: hal-00535819

<https://hal.science/hal-00535819>

Submitted on 13 Nov 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Accepted Manuscript

Title: Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations

Authors: Mansooreh Jaberipour, Simon O. Vass, Christopher P. Guise, Jane I. Grove, Richard J. Knox, Longqin Hu, Eva I. Hyde, Peter F. Searle



PII: S0006-2952(09)00678-9
DOI: doi:10.1016/j.bcp.2009.07.025
Reference: BCP 10282

To appear in: *BCP*

Received date: 2-6-2009
Revised date: 29-7-2009
Accepted date: 31-7-2009

Please cite this article as: Jaberipour M, Vass SO, Guise CP, Grove JI, Knox RJ, Hu L, Hyde EI, Searle PF, Testing double mutants of the enzyme nitroreductase for enhanced cell sensitisation to prodrugs: effects of combining beneficial single mutations, *Biochemical Pharmacology* (2008), doi:10.1016/j.bcp.2009.07.025

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Testing double mutants of the enzyme nitroreductase**
2
3
4 **for enhanced cell sensitisation to prodrugs: effects of**
5
6
7 **combining beneficial single mutations**
8
9

10
11 Mansoor Jaberipour^{a1}, Simon O. Vass^a, Christopher P. Guise^{a2}, Jane I. Grove^{a,3}, Richard J.
12
13 Knox^c, Longqin Hu^d, Eva I. Hyde^b and Peter F. Searle^{a§}
14
15

16
17 ^aCancer Research UK Institute for Cancer Studies, and ^bSchool of Biosciences, University of
18 Birmingham, Birmingham B15 2TT, UK. ^cMorvus Technology Ltd., Carmarthen SA32 8HZ
19
20 UK. ^dDepartment of Pharmaceutical Chemistry, Ernest Mario School of Pharmacy, Rutgers,
21
22 The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA.
23
24

25
26 Current addresses: ¹Institute for Cancer Research, Shiraz University of Medical Sciences,
27 Zand Street, Shiraz, Iran 71345- 3119. ²Auckland Cancer Society Research Centre,
28 University of Auckland, Private Bag 92019, Auckland, New Zealand; and ³Institute of
29 Genetics, Nottingham University School of Biology, Queen's Medical Centre, Nottingham,
30 NG7 2UH
31
32
33
34
35
36
37
38
39
40

41
42 **Category:** Antibiotics and Chemotherapeutics
43
44
45

46
47
48
49 ***Corresponding author:** Dr. P.F. Searle, Cancer Research UK Institute for Cancer Studies,
50 University of Birmingham, Birmingham B15 2TT, UK. Phone +44-121-414-4487; Fax +44-
51 121-414-4486; email p.f.searle@bham.ac.uk
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

1
2
3
4 Prodrug activation gene therapy for cancer involves expressing prodrug-activating enzymes in
5
6
7 tumour cells, so they can be selectively killed by systemically administered prodrug. For
8
9
10 example, *E. coli nfsB* nitroreductase (E.C. 1.6.99.7)(NTR), sensitises cells to the prodrug
11
12 CB1954 (5-[aziridin-1-yl]-2,4-dinitrobenzamide), which it converts to a potent DNA-
13
14 crosslinking agent. However, low catalytic efficiency with this non-natural substrate appears
15
16 to limit the efficacy of this enzyme-prodrug combination for eliminating the target cancer
17
18 cells. To improve this, we aim to engineer NTR for improved prodrug activation. Previously,
19
20 a number of single amino acid substitutions at 6 positions around the active site of the enzyme
21
22 were found to increase activity, resulting in up to ~5 fold enhanced cell sensitisation to
23
24 CB1954. In this study we have made pairwise combinations among some of the best mutants
25
26 at each of these 6 sites. A total of 53 double mutants were initially screened in *E. coli*, then
27
28 the 7 most promising were inserted into an adenovirus vector and compared in SKOV3
29
30 human ovarian carcinoma cells for sensitisation to CB1954 and two alternative prodrugs. The
31
32 most effective mutants, T41L/N71S and T41L/F70A, were 14–17-fold more potent than WT
33
34 NTR at sensitising the cancer cells to CB1954. The best mutant for activation of the
35
36 dinitrobenzamide mustard prodrug SN23862 was T41L/F70A (4.8-fold improvement); and
37
38 S40A/F124M showed 1.7-fold improvement over WT with the nitrobenzylphosphoramidate
39
40 mustard prodrug LH7. In two tumour xenograft models using SKOV3 or human prostate
41
42 carcinoma PC3, T41L/N71S NTR demonstrated greater CB1954-dependent anti-tumour
43
44 activity than WT NTR.
45
46
47
48
49
50
51

52
53
54
55
56
57
58 **Keywords:** nitroreductase; prodrugs; CB1954 (5-[(aziridin-1-yl)-2,4-dinitrobenzamide]); virus
59
60 directed enzyme prodrug therapy (VDEPT); cancer gene therapy
61
62
63
64
65

1. Introduction

Conversion of relatively non-toxic prodrugs to highly cytotoxic derivatives by enzymes that can be expressed selectively in cancer tissue following gene transfer (usually using a viral vector) is an attractive approach to cancer gene therapy, commonly known as gene (or virus) directed enzyme prodrug therapy (GDEPT or VDEPT) [1-8]. A number of different enzyme/prodrug combinations have been described [7, 9], including thymidine kinase (from herpes simplex virus) which activates the prodrug ganciclovir [10] and cytosine deaminase, which converts 5-fluorocytosine to 5-fluorouracil [11]. Both these systems inhibit DNA synthesis, leading to death of proliferating cells. We have focussed on cancer gene therapy using nitroreductase (NTR)(E.C. 1.6.99.7), encoded by the *nfsB* gene of *E. coli*, to activate the prodrug 5-[aziridin-1-yl]-2,4-dinitrobenzamide (CB1954) in an NAD(P)H-dependent reaction [3, 12-15]. The activated species generated by nitroreduction of CB1954 is a potent DNA alkylating agent that generates highly cytotoxic interstrand crosslinks in DNA [16], and is thus independent of ongoing cellular DNA replication for its cytotoxicity. The ability of activated CB1954 to kill both dividing and non-dividing cells may be an advantage when the target cells are not proliferating rapidly [7, 14, 17, 18]. Besides cancer gene therapy, NTR and CB1954 are also being used increasingly for other applications requiring conditional cell killing, including killing of cells responsible for loosening of orthopaedic implants in patients [19], and targeted, controllable tissue ablation in transgenic animals [20-24].

In clinical trials of prodrug activation gene therapy in cancer patients the desired level of efficacy has yet to be achieved with any enzyme-prodrug combination [4, 8, 25-27]. A recently completed phase I/II trial of a replication-defective adenovirus expressing NTR, injected intraprostatically in patients with locally recurrent prostate cancer and followed by intravenous infusion of CB1954, has shown reduction or stabilisation of the tumour marker

1 PSA (prostate specific antigen) in some patients [28], but greater efficacy is required.

2 We are therefore investigating a number of complementary strategies that could improve
3 efficacy, including co-expression of the cytokine GM-CSF [29], use of conditionally
4 replicating adenovirus vectors [30, 31], and engineering the enzyme NTR for greater catalytic
5 activity with CB1954 [32, 33].
6
7
8
9
10

11 Previous studies expressing NTR in cancer cells *in vitro* found the extent of cell killing
12 depended upon the level of NTR expression (related to dose of virus vector), and the
13 concentration of prodrug [12, 14]. Mouse tumour models also showed a dependency of anti-
14 tumour efficacy on virus dose [15]. These studies implied that the rate of CB1954 activation
15 is a significant limitation, and early kinetic studies of purified NTR indicated that CB1954 is
16 a relatively poor substrate for the enzyme, with apparent k_{cat} of just 6 s^{-1} and apparent K_{m} of
17 $\sim 860 \text{ }\mu\text{M}$ [34]. The global-fit parameters were recently reported to be appreciably higher (K_{m}
18 $17.2 \text{ mM} \pm 4.8 \text{ mM}$, $k_{\text{cat}} 140 \pm 32 \text{ s}^{-1}$) [35], although the specificity constant $k_{\text{cat}}/K_{\text{m}}$ is
19 consistent with the earlier study. In mice, the peak blood concentration of CB1954 following
20 intraperitoneal injection at a dose of 50 mg/kg was around $100 \text{ }\mu\text{M}$ [36]. The discrepancy
21 between K_{m} and substrate concentration is still greater in humans, since a dose-escalating
22 clinical trial of CB1954 found the maximum achievable plasma concentration of CB1954 was
23 only 5 – 10 μM [37], a concentration at which its reduction by NTR would be below 1% of its
24 maximum possible turnover rate. We propose that modified NTRs engineered for improved
25 catalytic activity with CB1954 should be beneficial, allowing the generation of more activated
26 prodrug, and thus give greater killing of the target cells, at equivalent doses of vector and
27 prodrug.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 Determination of the crystal structure of NTR with the substrate analogue nicotinic acid in the
55 active site allowed identification of amino acid residues that could directly influence substrate
56
57
58
59
60
61
62
63
64
65

1 binding and catalysis [38]. In a previous study we mutated each of 9 positions around
2 the active site of NTR to randomised codons, and screened the resulting mutants for their
3 ability to sensitise *E. coli* to CB1954 [32]. Any substitutions at residues E165 or G166 were
4 detrimental to prodrug activation. A small number of substitutions at G120 were tolerated, but
5 without significant improvement. In contrast, certain single amino acid substitutions at S40,
6 T41, Y68, F70, N71 and F124 each significantly improved the enzyme activity with CB1954,
7 giving at least 30% reduction in the IC₅₀ for the prodrug (*i.e.* the concentration required to
8 reduce viability by 50%) in *E. coli*. At S40, T41 or N71, just 1 – 3 amino acid substitutions
9 improved activity with CB1954. In contrast, at least 6 substitutions at either Y68 or F70
10 improved activity, and most strikingly, 14 different substitutions at F124 were found to
11 improve activity by between 2 and 6-fold. Using an adenovirus vector to express F124K-NTR
12 in SKOV3 human ovarian carcinoma cells showed it to be about 5-fold more potent than WT
13 NTR for cell sensitisation to CB1954 [32].
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

31 We postulated that further improvements in the ability of NTR to activate CB1954 might be
32 obtained by combinations of the beneficial single mutants identified previously. In this paper
33 we describe the generation of 53 NTR double mutants, containing 14 of the substitutions that
34 were most effective individually. These were tested initially in *E. coli*, and the 7 most
35 promising were inserted into adenovirus vectors and compared for sensitisation of human
36 carcinoma cells to CB1954, and two alternative prodrugs.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

2. Materials and Methods

2.1 Construction of lambda vectors containing NTR double mutants

The lambda vector λ JG3J1, and derivatives carrying WT NTR and all the single mutants used in this study were described previously [32]. Most NTR double mutants were generated from these by polymerase chain reaction (PCR)-mediated recombination. For example, double mutants combining changes at S40, T41, Y68, F70 or N71 with F124 substitutions used a 5' fragment amplified from the appropriate single mutant using primers JG14A (GACAATTAATCATCGGCTCG, within the *Ptac* promoter of the vector) and PS1013A (reverse primer GCTTCAGCCAGACATCGTCC, codons 97 – 90), and a 3' fragment amplified from the appropriate F124 mutant using primers JG127A (GAGCGTAAAATGCTTGATGCCTCG, codons 72 – 79) and JG2B (CAGAGCATTAGCGCAAGGTG, a reverse primer within vector sequence downstream of the gene). PCR reactions were performed using the high fidelity *Pfu* polymerase (Stratagene, La Jolla, CA, USA), using 5 min at 94°C for the initial denaturation, followed by 25 cycles of 94°C for 45 s, 55°C for 50 s, and 72°C for 50 s, and a final extension phase of 7 minutes at 72°C. After purification of the PCR products using a High Pure PCR Product Purification Kit (Roche Diagnostics Ltd., Burgess Hill, UK), approximately 10 – 20 ng of the appropriate 5' and 3' fragments were combined using a further, similar PCR reaction with the two flanking primers. The full length PCR product was then digested with *Sfi* I (New England Biolabs UK Ltd, Hitchin, UK), and cloned between the corresponding *Sfi* I sites of the lambda vector λ JG3J1 [32].

To make the double mutants S40A/T41L and F70A/N71S, the 5' fragments were amplified using primers JG14 A and the reverse, mutagenic primers PS1263A

1 (CAACAATAAAATGCCACGGCTGGGAGTTCAGCGCGGATGGGCTGTATTGCAG) or
2 PS1263B (CGAGGCATCAAGCATTTTACGCTCGGACGCCACGTAATTACCGGCAGCG),
3
4 respectively (mutated codons underlined). The 3' fragments were amplified using primers
5
6 JG126A (CCCAGCCGTGGCATTTTATTGTTG, codons 43-51) or JG127A, respectively, and
7
8 downstream primer JG2B. After cloning into λ JG3J1, the DNA was packaged into lambda
9
10 particles using a Gigapack III Plus Packaging Extract (Stratagene, La Jolla, CA, USA), and
11
12 used to infect *E. coli* UT5600, which has a deletion of the endogenous *nfsB* gene (also known
13
14 as *nfnB*) encoding NTR. Lysogenised clones were selected by spreading on agar plates
15
16 containing 30 μ g/ml kanamycin (Sigma-Aldrich, Poole, UK). Clones were sequenced through
17
18 the NTR gene to confirm their identity and the absence of additional mutations.
19
20
21
22
23
24

25 **2.2 Bacterial prodrug sensitivity assays**

26
27 Both the replica plating assay, and the colony forming assay, were performed as described
28
29 previously [32]. GraphPad Prism 4 (GraphPad Software Inc., La Jolla, CA, USA) was used to
30
31 fit sigmoid curves to the data of colony number versus prodrug concentration by nonlinear
32
33 regression, constraining the limits to 100% and 0, and with a shared Hillslope for all the
34
35 datasets, to determine the IC_{50} s, which were compared by F-test.
36
37
38
39
40
41

42 **2.3 Detection of NTR by western blotting**

43
44 For comparison of NTR expression levels in bacteria, the lysogen cultures were grown to
45
46 OD_{600} 0.5 in LB medium containing 0.1 mM isopropyl β -D-thiogalactopyranoside (IPTG,
47
48 Sigma-Aldrich) then the bacteria from 100 μ l of the cultures were pelleted by centrifugation
49
50 at 13000 rpm in a microcentrifuge, and lysed in 10 μ l of 1x SDS-PAGE loading buffer (2%
51
52 SDS, 10% glycerol, 6M urea, 100 mM DTT, 80 mM Tris pH 6.8, 0.01% bromophenol blue,
53
54 all from Sigma-Aldrich), heated to 95°C for 5 min and separated on a SDS-polyacrylamide
55
56
57
58
59
60
61
62
63
64
65

1 gel (12%) (Geneflow, Fradley, UK). For comparison of NTR expression in SKOV3
2
3 cells infected with the viruses, 3.6×10^5 cells infected with 100 infectious units (iu)/cell of the
4
5 different NTR-expressing adenoviruses were plated in 6-well plates and cultured for 48 hours,
6
7 before washing twice with 2 ml phosphate buffered saline (PBS; Oxoid, Basingstoke, UK)
8
9 then lysing the cell sheet with 0.5 ml 8M urea (Sigma-Aldrich). The protein concentration
10
11 was determined by Bradford assay [39] (Bio-Rad Laboratories, Munich, Germany), and 10 μ g
12
13 of protein was loaded per well of the SDS-polyacrylamide gel (12%), after mixing with an
14
15 equal volume of 2x SDS-PAGE loading buffer and heating to 95°C for 5 min.
16
17
18
19

20
21 After electrophoresis and transfer to PVDF membrane (Bio-Rad Laboratories), NTR was
22
23 detected using a polyclonal sheep anti-NTR primary antibody kindly provided by ML
24
25 Laboratories, plc, while β -tubulin was detected using a mouse monoclonal antibody (Sigma-
26
27 Aldrich). Donkey anti-sheep and goat anti-mouse peroxidase-conjugated secondary antibodies
28
29 (both from Sigma-Aldrich) were applied prior to detection using an Amersham ECL Plus
30
31 Western Blotting Kit (GE Healthcare, Chalfont St. Giles, UK) and Amersham Hyperfilm
32
33 ECL.
34
35
36
37
38

39 **2.4 Adenovirus vectors**

40
41
42 The NTR mutants of interest were amplified by PCR from the appropriate lambda vector
43
44 using primers JG138A (GCACGCTAGCAAGCTTCCACCAATGGGATATCATTTCTGTCGCC,
45
46 start codon underlined) and JG138B
47
48 (GCACAAGCTTGCTAGCTCATTACACTTCGGTTAAGGTGATG, stop codon underlined),
49
50 and cloned under the control of the CMV promoter in the replication-defective adenovirus
51
52 vector vPS1233 [32], in which the NTR coding region is followed by an IRES (internal
53
54 ribosome entry site, derived from poliovirus) and the enhanced green fluorescent protein
55
56 (EGFP) coding sequence. The full-length virus genomes were constructed as plasmids, and
57
58
59
60
61
62
63
64
65

1 the virus rescued by calcium phosphate-mediated transfection into HEK293 cells [40].

2
3 The virus was expanded on HEK293 cells, and purified by density-gradient centrifugation
4
5 using CsCl (Invitrogen, Paisley, UK). The NTR genes in the viruses were sequenced to
6
7 confirm identity. The concentration of virus particles was determined by DNA assay using
8
9 Pico Green (Invitrogen). The infectious titre of the virus (infectious units, iu/ml) was
10
11 determined by flow cytometry for detection of EGFP expression, 24 h after infection of 911
12
13 cells [41] with a range of virus dilutions. For the different viruses the ratio of virus particles to
14
15 iu was between 16 and 29.
16
17
18
19
20

21 **2.5 SKOV3 cell prodrug sensitivity assay**

22
23
24 Monolayer cultures of SKOV3 ovarian carcinoma cells were harvested and infected in
25
26 suspension with 100 iu/cell of the viruses expressing either WT NTR, the NTR mutants, or
27
28 just EGFP as a control, before plating 10,000 cells/well in a 96-well plate. Two days later the
29
30 culture medium was replaced with fresh medium containing a range of prodrug concentrations
31
32 (0, 0.1–300 μ M). (CB1954 was a kind gift from ML Laboratories and from Morvus
33
34 Technology, Ltd; SN23862 was a kind gift from Morvus Technology Ltd; LH7 was
35
36 synthesized as described [42]). After 4 h the medium was again replaced with fresh medium
37
38 without prodrug, and the cells were cultured for a further 3 days, before assay of viability
39
40 using the chromogenic substrate MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
41
42 bromide; Sigma-Aldrich) [43]. Data were analysed using GraphPad Prism; to determine IC₅₀
43
44 values, sigmoid curves were fitted to the data for % cell survival and log₁₀ of prodrug
45
46 concentration, constraining the upper and lower limits to 100% and 0. The derived IC₅₀ values
47
48 for viruses with the different NTR variants were compared by F-test.
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

2.6 *In vivo* experiments

1
2
3
4 The WT and T41L/N71S NTR coding sequences were amplified by PCR from *E. coli* DNA
5
6 or the corresponding lambda vector, respectively, using primers
7
8 AGCCGCCACCATGGATATCATTCTGTCGCC and
9
10 GGATCCTCATTACACTTCGGTTAAGGTGATG, and inserted into the *Hpa* I site
11
12 downstream of the CMV promoter in the retroviral vector plasmid pxLNCX [44]. The
13
14 resulting plasmids were transfected into the packaging cell line FLY-A13 [45], and pools of
15
16 stably transfected cells selected with G418 (500 µg/ml; Sigma-Aldrich). Retrovirus-
17
18 containing supernatant from these was filtered (0.45 µm) and used to infect SKOV3 cells,
19
20 which were subsequently selected with G418 (500 µg/ml). A number of G418-resistant clones
21
22 were selected by limiting dilution. Cell lysates were analysed by western blotting to compare
23
24 levels of NTR expression, and two clones (referred to hereafter as SKOV3-NTR_{WT} and
25
26 SKOV3-NTR_{T41L/N71S}) that were best matched for expression of WT and T41L/N71S NTR
27
28 were chosen for further experiments.
29
30
31
32
33
34
35

36 Tumours were seeded in Balb/c nude mice by subcutaneous injection of 5×10^6 SKOV3-
37
38 NTR_{WT} or SKOV3-NTR_{T41L/N71S} cells in 100 µl PBS, mixed with an equal volume of Matrigel
39
40 High Concentration (BD Biosciences, Oxford, UK). Tumours were measured with callipers 3
41
42 times each week. Tumour volume was calculated as $(L \times W^2 \times 0.5)$, where L and W are
43
44 respectively the longest dimension, and the perpendicular width of the tumour. The mice were
45
46 treated with 3 daily intraperitoneal injections of CB1954 (each 20 mg/kg, using a 1 mg/ml
47
48 solution, with 1.25 % *N*-methyl pyrrolidone and 4.37% polyethylene glycol 300 (both from
49
50 Sigma-Aldrich), in PBS) or vehicle alone, when tumours reached a size of $\sim 100 - 150 \text{ mm}^3$.
51
52
53 For the SKOV3-NTR_{T41L/N71S} tumours, treatment with prodrug (16 mice) or vehicle (5 mice)
54
55
56
57
58 commenced 14 days after tumour seeding; however the SKOV3-NTR_{WT} tumours grew more
59
60
61
62
63
64
65

1 slowly, so treatment was delayed until 32 days (14 mice: 9 with prodrug, 5 with
2 vehicle) or 55 days (7 mice: 3 with prodrug, 4 with vehicle) following inoculation.
3
4

5
6 In another experiment, adenoviruses vPS1306 and vPS1307 were used to express WT or
7
8 T41L/N71S, respectively, in the tumour cells. These viruses are similar to those based on
9
10 vPS1233 described above, but express human granulocyte macrophage colony stimulating
11
12 factor (GM-CSF) rather than EGFP, following the IRES downstream of the inserted NTR
13
14 gene. (Human GM-CSF lacks biological activity in mice, and its expression was not
15
16 monitored in this experiment. The titre of these viruses was determined by plaque titration on
17
18 911 cells.) Human PC3 prostate carcinoma cells were infected *in vitro* by incubation for 1.5 h
19
20 with 100 plaque forming units (pfu)/cell of either vPS1306 or vPS1307, then washed twice
21
22 with PBS before resuspension in PBS, and subcutaneous injection of 5×10^6 cells into NOD-
23
24 SCID mice. Residual cells were plated in 96-well plates as described above, and assayed for
25
26 sensitivity to CB1954. Ten mice received cells infected with vPS1306 (expressing WT NTR),
27
28 10 received cells infected with vPS1307 (expressing T41L/N71S NTR) and 10 received
29
30 mock-infected cells. On the second and third days, 6 animals from each group were injected
31
32 with 30 mg/kg CB1954, while the other 4 received vehicle alone. Tumour size was monitored
33
34 as above. Experiments using animals were conducted under an appropriate UK Home Office
35
36 Licence and in accordance with Guidelines issued by the UK Coordinating Committee on
37
38 Cancer Research.
39
40
41
42
43
44
45
46
47
48
49
50

51 **3. Results**

52
53
54
55
56 NTR is a homodimeric flavoprotein with FMN tightly bound in both active sites, which are
57
58 equivalent, and formed at the interface between the 24 kD subunits [38, 46]. Figure 1A
59
60
61
62
63
64
65

1 illustrates one active site of WT NTR, showing the 6 amino acid residues at which
2
3 beneficial amino acid substitutions were found previously [32]. Between one and seven of the
4
5 most beneficial single mutants at each of these sites (S40A or -G, T41L, Y68G, F70A or -V,
6
7 N71S, and F124H, -K, -M, -N, -Q, -S or -W) were combined to give a total of 53 double
8
9 mutants, as indicated by the matrix in Figure 1B. These double mutants were cloned into the
10
11 bacteriophage lambda vector λ JG3J1 [32] and used to generate *E. coli* lysogens, in which a
12
13 single, quiescent copy of the lambda prophage is stably inserted into the bacterial
14
15 chromosome and the inserted NTR gene is expressed from the IPTG-inducible *Ptac* promoter.
16
17
18
19
20

21 **3.1 Testing NTR mutants in *E. coli***

22
23
24 The NTR mutants were first screened for their ability to sensitise *E. coli* to CB1954 by replica
25
26 plating cultures of the bacterial lysogens onto a series of agar plates, each containing a
27
28 different concentration of CB1954. In this assay, lysogens expressing the most active NTR
29
30 mutants are killed at lower prodrug concentrations than those expressing WT NTR, while
31
32 bacteria lacking NTR activity are resistant and able to grow even at high CB1954
33
34 concentrations. A typical example of replica plating is shown in Figure 2A. All the lysogens
35
36 were able to grow in the absence of prodrug. A few, including the single mutant F124N and
37
38 double mutants T41L/N71S and N71S/F124N did not grow on plates containing 25 μ M
39
40 CB1954, but most clones survived this prodrug concentration. Successively fewer clones
41
42 were able to grow on plates containing 50 and 100 μ M CB1954. The bacteria expressing WT
43
44 NTR could survive at 100 but not at 200 μ M CB1954, while lysogens carrying the empty
45
46 vector and hence lacking NTR grew well even at 200 μ M prodrug. Surprisingly, a number of
47
48 the double mutants were also capable of growth at 200 μ M CB1954, implying these enzymes
49
50 were less efficient than WT NTR or the contributing single mutants.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Table 1 shows the results from a similar experiment, in which the lysogens were
2
3 replica plated onto agar containing 0, 20, 30, 45, 90 or 180 μM CB1954, and each mutant is
4
5 listed at the highest prodrug concentration at which growth was observed. F124N was the best
6
7 single mutant previously identified [32] and this was confirmed here; in this assay it was
8
9 capable of growth only at 20 μM CB1954, whereas all the other single mutants survived up to
10
11 45 μM CB1954. Six double mutants were also capable of growth only at 20 μM CB1954,
12
13 including combinations of S40A with F124K, -M and -N, and combinations of N71S with
14
15 T41L, F124K or F124N. Thus 4 of these double mutants (S40A/F124K, S40A/F124M,
16
17 T41L/N71S and N71S/F124K) were clearly improved relative to the corresponding single
18
19 mutants. Notably, other combinations of the same single mutants were less beneficial; for
20
21 example, S40A/T41L was able to grow at 45 μM CB1954 and S40A/N71S survived at 90 μM
22
23 CB1954.
24
25
26
27
28
29

30 To better discriminate the ability of the most promising mutants to sensitise *E. coli* to
31
32 CB1954, the seven best double mutants, and the single mutants F124K and F124N, were
33
34 tested more quantitatively in a colony-forming assay, in which a dilute suspension of the
35
36 bacterial lysogens is plated on agar containing different concentrations of CB1954, and the
37
38 number of colonies formed after overnight incubation is counted. Figure 2B shows examples
39
40 of the dose-response curves for bacteria expressing different NTR mutants, plotting the
41
42 plating efficiency (number of colonies, as a percentage of the number that grow in the absence
43
44 of prodrug) against CB1954 concentration. Sigmoid curves were fitted to the data to allow
45
46 estimation of the prodrug concentrations required to give a 50% reduction in plating
47
48 efficiency (IC_{50}). The IC_{50} s for these 9 mutants and WT NTR are listed in Table 2. Whereas
49
50 all the mutants had been able to grow at 20 μM CB1954 in the replica plating assay, the IC_{50}
51
52 for most of these mutants was significantly lower than this. We attribute this difference to the
53
54 greater stringency of the colony-forming assay, which scores the survival or death of
55
56
57
58
59
60
61
62
63
64
65

1 individual plated bacteria, whereas in the replica plating assay each inoculum contains
2
3 a large number of bacteria, and survival of only a small proportion of these may be sufficient
4
5 to allow visible growth. The mutant conferring greatest sensitivity to CB1954 was
6
7 T41L/N71S, for which the IC_{50} was determined as $11.4 \pm 1.2 \mu\text{M}$ CB1954, significantly
8
9 lower than the IC_{50} of $18.3 \pm 1.4 \mu\text{M}$ CB1954 for the best single mutant, F124N ($P < 0.0001$).
10
11 Five of the other double mutants gave IC_{50} s intermediate between these values, whereas that
12
13 for T41L/F70A was $20.4 \mu\text{M}$ CB1954, still much better than WT NTR ($IC_{50} 145 \pm 3.5 \mu\text{M}$).
14
15
16
17
18 The expression of these seven most effective NTR double mutants, as well as selected single
19
20 mutants and two double mutants (S40G/F124N and Y68G/F124N) that conferred lower
21
22 sensitivity to CB1954 than WT NTR, was compared by western blotting of protein samples
23
24 from cultures of the lysogens in exponential growth. As shown in Figure 2C, the mutant
25
26 NTRs all co-migrated with WT, and variations in level of expression were relatively minor.
27
28
29 Importantly, this showed that the variation in prodrug sensitivity could not be explained
30
31 simply by variation in the level of enzyme expression. It therefore appears that the improved
32
33 sensitisation to prodrug by these mutant NTRs must be determined principally by increased
34
35 specific activity of the enzymes with CB1954.
36
37
38
39
40

41 **3.2 Testing NTR mutants in human carcinoma cells**

42
43
44 The results from the bacterial colony forming assay (Figure 2B and Table 2) indicated that
45
46 each of the seven best double mutants, as well as F124N, appeared significantly more
47
48 efficient at sensitising the bacteria to CB1954 than F124K, the only NTR mutant previously
49
50 tested in human cells [32]. We therefore inserted each of these 7 NTR double mutants, and
51
52 also the single mutants T41L and F124N, into the same replication-defective adenovirus
53
54 vector. The viruses expressing the different NTR mutants were tested for their ability to
55
56 sensitise SKOV3 ovarian carcinoma cells to CB1954. CB1954 dose-response curves from a
57
58
59
60
61
62
63
64
65

1 representative experiment are shown in Figure 3A; (some lines have been omitted for
2 clarity). Cells infected with a control adenovirus expressing just EGFP showed no reduction
3 in viability over the range of CB1954 concentrations tested (up to 300 μM), whereas infection
4 with the virus expressing WT NTR resulted in an IC_{50} of $\sim 12 \mu\text{M}$ CB1954. Surprisingly, the
5 viruses expressing either the N71S/F124N mutant, or N71S/F124K (not shown) were
6 markedly less effective in sensitising cells to CB1954, with IC_{50} s around 90 – 100 μM
7 CB1954. The IC_{50} for cells expressing F124K was about 4-fold lower than for WT NTR,
8 consistent with previous results [32]. The single mutant F124N caused almost 6-fold greater
9 sensitivity than WT NTR. The lowest IC_{50} s were achieved by the double mutants T41L/F70A
10 and T41L/N71S (0.82 and 0.92 μM CB1954, respectively). Table 3 summarises the fold
11 improvement (*i.e.* reduction in IC_{50}) for each NTR mutant relative to WT, averaged across 3
12 separate experiments. Some of these NTR mutants (F124N, T41L, S40A/F124K, T41L/N71S
13 and N71S/F124N, and WT NTR) were also tested in liver (HepG2), colorectal (SW480) or
14 prostate (PC3) carcinoma cell lines, where their rank order of activity was the same as in
15 SKOV3 cells.
16

17 The levels of expression of the NTR mutants in the infected SKOV3 cells were compared by
18 western blotting. As shown in Figure 4 there was some variation in the level of expression of
19 the different NTR mutants, with N71S/F124K and N71S/F124N in particular being expressed
20 at a much lower level, which may explain the poor sensitisation to CB1954 achieved with
21 these mutants in all the human cell lines. The levels of T41L/F70A and T41L/N71S
22 expression were similar to WT.
23

24 The NTR mutants were also tested for their ability to sensitise SKOV3 cells to two alternative
25 prodrugs, the dinitrobenzamide mustard SN23862 [47] and the 4-nitrobenzylphosphoramidate
26 mustard prodrug LH7[42]. The results of 2 experiments are summarised in Table 3, and
27

1 representative data are shown in Figure 3B and C. Consistent with their poor levels of
2 expression, N71S/F124K and N71S/F124N were much less effective than WT NTR at
3 sensitising SKOV3 cells to either prodrug. For SN23862, most other mutants showed similar
4 efficacy to WT NTR (0.9 – 2-fold improvement), however S40A/F124M and T41L/F70A
5 conferred 3.7 and 4.8-fold greater sensitivity, respectively. For LH7, most of the mutants
6 were clearly less effective than WT NTR (~0.1 – 0.9 times as effective), and only
7 S40A/F124M showed a modestly (~1.7-fold) improved sensitisation.
8
9

10 **3.3 Sensitisation of tumours to CB1954 in vivo**

11 Retrovirus vectors were used to generate clones of SKOV3 cells stably expressing either WT
12 or T41L/N71S NTR. These SKOV3-NTR_{WT} and SKOV3-NTR_{T41L/N71S} cells were injected
13 subcutaneously in athymic nude mice. When the tumours reached approximately 100 – 150
14 mm³, the animals were treated with 3 daily injections of CB1954 or vehicle. For the SKOV3-
15 NTR_{T41L/N71S} tumours, treatment commenced 14 days after tumour inoculation; however the
16 SKOV3-NTR_{WT} tumours took longer to establish, and so treatment did not commence until
17 32 or 55 days after tumour inoculation. The mean tumour volumes of the different treatment
18 groups are plotted as a function of time following treatment in Figure 5A and 5B, for the
19 tumours expressing WT or T41L/N71S NTR, respectively. Treatment with CB1954 did not
20 reduce the growth of the tumours with WT NTR, relative to those receiving vehicle (Fig. 5A).
21 However growth of the tumours expressing T41L/N71S was strongly inhibited by CB1954,
22 whereas they continued to grow in mice injected with vehicle (Fig. 5B). At 33 days after
23 treatment of the SKOV3-NTR_{T41L/N71S} tumours, the first of the vehicle-treated mice was
24 humanely killed because of tumour burden; at this time, the tumours in the CB1954-treated
25 group were significantly smaller than those treated with vehicle only (P = 0.006, Mann-
26 Whitney test, 2-tailed). Some mice developed age-related morbidities before their tumours
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 developed to a size necessitating sacrifice; we have therefore used a tumour size of 500
2 mm³ as cut-off for Kaplan-Meier analysis of “survival” post-treatment (Figure 5C).
3
4 Consistent with the more rapid growth of the SKOV3-NTR_{T41L/N71S} tumours before treatment,
5 these tumours reached 500 mm³ the soonest after treatment, when treated with vehicle only.
6
7 Treatment of these tumours with CB1954 significantly delayed their growth to 500 mm³ (P
8 <0.0001, log-rank test). The slower growth of the SKOV3-NTR_{WT} tumours before they
9 reached a treatable size was reflected in slower further growth than the vehicle-treated
10 SKOV3-NTR_{T41L/N71S} tumours to 500 mm³; however CB1954 treatment was not associated
11 with any growth delay of the SKOV3-NTR_{WT} tumours. Despite the intrinsically faster growth
12 of the SKOV3-NTR_{T41L/N71S} tumours, treatment of these with CB1954 extended the median
13 tumour growth delay of this group beyond that of either SKOV3-NTR_{WT} treatment group;
14 however this difference did not quite reach statistical significance (P = 0.08, comparing both
15 CB1954 treatment groups). The cell clones were initially chosen as having the best matched
16 levels of NTR expression, nevertheless as shown in Figure 5D the enzyme was clearly more
17 highly expressed in SKOV3-NTR_{WT} than in SKOV3-NTR_{T41L/N71S} cells, supporting the
18 interpretation that the improved response of the SKOV3-NTR_{T41L/N71S} tumours is attributable
19 to improved prodrug activation by T41L/N71S NTR.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 We recently reported a phase I/II clinical trial of prodrug activation gene therapy using a
43 nitroreductase-expressing adenovirus and CB1954 in prostate cancer [28]. We therefore also
44 tested the T41L/N71S NTR mutant in a prostate cancer xenograft model. PC3 prostate
45 carcinoma cells were infected *in vitro* using 100 pfu/cell of adenovirus vectors expressing WT
46 or T41L/N71S NTR, before subcutaneous injection in NOD-SCID mice. This dose of virus
47 was shown to infect >95% of PC3 cells, and the cells infected with the T41L/N71S-
48 expressing virus were 5-fold more sensitive to CB1954 than those with WT NTR (data not
49 shown). On the second and third day after cell injection, the mice were injected with either
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 CB1954 or vehicle; mean tumour sizes of the different treatment groups are shown in
2
3 Figure 6. Treatment with CB1954 caused minimal growth delay of uninfected PC3 cells (time
4
5 to reach mean tumour volume of 200 mm³ — 33 *versus* 36 days). Infecting the cells with
6
7 adenovirus expressing T41L/N71S or WT NTR delayed tumour growth (52 and 63 days to
8
9 reach 200 mm³, respectively). Combining WT NTR with CB1954 caused no additional delay
10
11 to reach 200 mm³. In contrast, combining the T41L/N71S virus with CB1954 extended the
12
13 time to reach 200 mm³ mean tumour volume, relative to the virus alone, from 52 to 97 days.
14
15 For the groups treated with the T41L/N71S virus, comparison of tumour sizes on day 66
16
17 (when the first animal was culled due to tumour size) showed a significant reduction in
18
19 tumour growth associated with CB1954 treatment ($P < 0.05$, Mann-Whitney test, 2-tailed). The
20
21 first of the group with WT-NTR treated tumours had to be culled on day 73; at this time there
22
23 was no significant difference in tumour size with or without CB1954. Among the groups
24
25 treated with CB1954, the difference in mean tumour size between the groups with WT or
26
27 T41L/N71S NTR also did not reach statistical significance.
28
29
30
31
32
33
34
35
36
37
38

39 4. Discussion

40
41
42
43 The aim of this work was to generate mutants of *E. coli* nitroreductase with improved ability
44
45 to convert the prodrug CB1954 to cytotoxic derivatives, since the rate of this conversion is
46
47 one of several factors that may limit the efficacy of prodrug activation gene therapy for
48
49 cancer. *E. coli* that over-express NTR are also susceptible to CB1954 toxicity, and because it
50
51 is much more straightforward to assay large numbers of mutants in bacteria than in human
52
53 cells, our strategy has been to screen NTR mutants for improved activity versus WT-NTR in
54
55 *E. coli*, before proceeding to insert the most promising mutants into an adenovirus vector for
56
57 testing in human carcinoma cells. Previous work in our laboratory found that single amino
58
59
60
61
62
63
64
65

1 acid substitutions at 6 positions around the active site of NTR could provide 2 – 6-fold
2 increased sensitisation of *E. coli* to CB1954, and it was confirmed that the F124K mutant
3 provided a similarly improved sensitisation of SKOV3 ovarian carcinoma cells [32]. In this
4 study we have tested the hypothesis that combining the best single mutants of NTR into
5 double mutants could further improve the activity of the enzyme with CB1954.
6
7

8
9
10
11 Initial screening by replica plating of 53 double mutants expressed in *E. coli* indicated that
12 only 7 showed clear improvement over both constituent single mutants. Nearly half of the
13 double mutants showed reduced prodrug sensitivity, while 21 had comparable prodrug
14 sensitivity, to the better contributing single mutant. As before [32], F124N was found to be
15 the most active single mutant, and this substitution was also present in two of the most active
16 double mutants, in combination with S40A and N71S. However, combinations of F124N with
17 other mutants resulted in reduced sensitisation to CB1954, either to a level comparable to the
18 other contributing mutant (T41L and F70V), or worse (when combined with Y68G). Thus,
19 the effects of pairwise combinations of the single mutants on prodrug sensitivity are not
20 simply additive, but can result in either little change, or greater or lesser activity with the
21 prodrug substrate than the contributing single mutants. This contrasts with a recent study on
22 directed, divergent evolution of terpene synthases, in which combining mutations in a number
23 of residues around the active site allowed predictable, progressive improvement in alternative
24 reaction pathways towards a number of different reaction products [48]. One possible reason
25 for the difference may be that the substrate of terpene synthase is an extended chain with
26 some flexibility, which may allow amino acid side-chain interactions to contribute relatively
27 independently to the binding and orientation of different groups on the substrate. In contrast,
28 CB1954 is a relatively rigid substrate that will require appropriate placement relative to the
29 FMN.H₂ in the active site of the enzyme for its reduction, hence changing any one point of
30 interaction with the protein is more likely to have knock-on consequences for other points of
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 interaction, reducing the number of combinations that are beneficial. Nevertheless, out
2
3 of the 53 NTR double mutants analysed, 7 were clearly better than all the single mutants other
4
5 than F124N, to which they appeared similar in efficacy. In the more stringent and
6
7 discriminatory colony-forming assay, six of these double mutants were shown to confer
8
9 greater sensitivity to CB1954 than F124N. The spread of IC_{50} s in bacteria was modest, from
10
11 18.3 μ M CB1954 for F124N down to 11.4 μ M CB1954 for T41L/N71S, but all pairwise
12
13 comparisons between either F124N or T41L/N71S and the other mutants appeared
14
15 statistically significant ($P < 0.0042$, and most < 0.001 , F test). Both F124N and each of these 7
16
17 double mutants clearly improved the sensitisation of *E. coli* to CB1954 in comparison with
18
19 F124K, the only mutant previously compared to WT NTR in human cells [32]. Each of these
20
21 was therefore inserted into a replication-defective adenovirus vector and tested for
22
23 sensitisation of SKOV3 human carcinoma cells to CB1954.
24
25
26
27
28
29

30 The greatest sensitisation of SKOV3 cells to CB1954 was obtained with two double mutants,
31
32 T41L/N71S and T41L/F70A (14 – 17-fold reduction in IC_{50}). The performance of the latter
33
34 was somewhat better than predicted by the bacterial assay, while others, especially
35
36 N71S/F124K and N71S/F124N, were less effective in human cells than anticipated. Despite
37
38 expressing all the NTRs from the identical adenovirus vector, western blotting demonstrated
39
40 clear variation in the level at which the different enzymes were expressed, with N71S/F124K
41
42 and N71S/F124N being particularly poorly expressed. Such differences might potentially
43
44 arise due to changes in the secondary structure of the mRNA, as a result of the nucleotide
45
46 changes associated with the mutations affecting either translation or mRNA stability;
47
48 alternatively, the combination of amino acid substitutions in the proteins might affect their
49
50 stability in the environment of eukaryotic cell cytoplasm. Notably, other combinations of the
51
52 contributing single mutations showed no apparent detriment to expression levels, so an effect
53
54 of codon preferences appears unlikely. Clearly, variation in the amount of NTR expressed per
55
56
57
58
59
60
61
62
63
64
65

1 infectious virus particle (Figure 4) can contribute to some of these differences in
2 efficacy. However, S40A/F124K appears to be expressed as well as WT, yet gave only 5-fold
3 improved sensitisation of SKOV3 cells, compared with ~10-fold improved sensitisation of
4 bacteria, compared to WT NTR. An additional possible reason for discrepancies between the
5 assays using bacteria and SKOV3 cells could be that some intracellular metabolites that differ
6 qualitatively or quantitatively between *E. coli* and human carcinoma cells might act as
7 inhibitors of the enzyme, the mutants having different relative affinities for the inhibitor
8 versus CB1954. Thus, the SKOV3 cell assay using adenovirus to deliver the mutant NTRs
9 measures the net effects of improvements in catalytic activity of the enzymes, variation in
10 efficiency of expression per virus particle in human cells, and possible additional influences
11 of the cellular milieu on the efficiency with which the enzyme can activate CB1954 in cancer
12 cells. Kinetic studies using purified enzymes have shown that the T41L/N71S mutant has a
13 100-fold greater specificity constant (k_{cat}/K_m) for CB1954 than WT NTR, due largely to a
14 corresponding reduction in K_m [35]. The extent to which T41L/N71S improves the
15 sensitisation of either *E. coli* or human cells to CB1954 relative to WT NTR is considerably
16 lower than the difference in their specificity constants might imply; the difference could be
17 explained in part by a 6-fold higher K_m of the mutant for the cofactor NADH, besides the
18 possible influence of other intracellular metabolites.

19 The mutants were also compared for their ability to sensitise SKOV3 cells to two alternative
20 prodrugs. SN23862 is a mustard analogue of CB1954; it has the potential advantage of
21 demonstrating greater bystander cell killing than CB1954 [49, 50], a property shared with
22 several other dinitrobenzamide mustard prodrugs [51]. The nitrobenzyl phosphoramidate
23 mustard LH7 is about 10-fold more cytotoxic than CB1954 to cells expressing WT-NTR,
24 attributable to improved kinetics of activation [52]. In general, NTR variants having improved
25 activity relative to WT-NTR with CB1954 also demonstrated some improved activity with
26

1 SN23862 (Table 3), as might be anticipated in view of the structural similarities
2
3 between the prodrugs (Figure 3A and 3B, insets). However there were differences in the
4
5 relative efficacies of the mutants for these two prodrugs, and the extent of improvement was
6
7 in all cases lower than for CB1954. Greatest sensitisation to SN23862 (4.8-fold) was achieved
8
9 by T41L/F70A. Most mutants were much less effective than WT-NTR with the structurally
10
11 dissimilar prodrug LH7, with only S40A/F124M showing modest (1.7-fold) improvement.
12
13 Thus, the effects of the mutations clearly show substrate selectivity.
14
15

16
17
18 We went on to test the potential benefit of using T41L/N71S rather than WT NTR to sensitise
19
20 tumours in mice to CB1954, using two xenograft tumour models. We initially used SKOV3
21
22 cell lines stably expressing the enzymes. Although SKOV3-NTR_{WT} tumours grew more
23
24 slowly than those expressing T41L/N71S NTR, only the latter showed a strong inhibition of
25
26 tumour growth following treatment with CB1954. (Note that the level of WT NTR expression
27
28 in the SKOV3-NTR_{WT} cell clone used here appears at least 10-fold lower than in the SKOV-
29
30 NTR cells previously shown to give a tumour response to CB1954 [12], data not shown). In a
31
32 second model using the human prostate carcinoma PC3, outgrowth of tumours from the cells
33
34 infected with adenovirus expressing WT NTR showed no effect of CB1954, whereas
35
36 expression of the T41L/N71S NTR was associated with delayed tumour outgrowth in animals
37
38 treated with CB1954. Thus, these experiments indicate that the benefit of increased prodrug
39
40 sensitivity conferred by the NTR mutants in cell culture can also translate to improved tumour
41
42 sensitisation to CB1954 *in vivo*.
43
44
45
46
47
48
49

50
51 In summary, this study has demonstrated that the properties of NTR variants combining two
52
53 single mutations cannot be simply predicted from the properties of the single mutants.
54
55 Nevertheless from a screen of 53 double mutants we have identified T41L/F70A and
56
57 T41L/N71S as promising NTR variants providing 14 – 17-fold improved sensitisation of
58
59
60
61
62
63
64
65

1 human carcinoma cells to CB1954. Furthermore, T41L/N71S NTR was shown to give
2 better anti-tumour activity with CB1954 than WT NTR, using two tumour xenograft models.
3
4 For future clinical trials of prodrug activation gene therapy using nitroreductase and CB1954,
5
6 consideration should be given to using one of these improved NTR mutants rather than the
7
8
9
10 WT enzyme.

11 **Acknowledgements**

12
13 MJ acknowledges the Iranian Ministry of Health and Medical Education for support. We
14
15
16 thank Scott White (School of Biosciences, University of Birmingham) for making Figure 1A,
17
18
19 Liz Hodgkins (Institute for Cancer Studies, University of Birmingham) for technical
20
21
22 assistance, and Vivien Mautner (Institute for Cancer Studies, University of Birmingham) for
23
24
25 helpful discussions. We acknowledge financial support from ML Laboratories plc (JIG), the
26
27
28 Medical Research Council (Grant number G9806623/44940) and Cancer Research UK (Grant
29
30
31 number C1007/A6688).
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

- 1
2
3
4 [1] Pandha HS, Martin LA, Rigg A, Hurst HC, Stamp GW, Sikora K, et al. Genetic
5
6 prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed
7
8 suicide gene expression. *J Clin Oncol* 1999;17:2180-9.
9
- 10
11 [2] Freytag SO, Stricker H, Pegg J, Paielli D, Pradhan DG, Peabody J, et al. Phase I study
12
13 of replication-competent adenovirus-mediated double-suicide gene therapy in
14
15 combination with conventional-dose three-dimensional conformal radiation therapy
16
17 for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.
18
19 *Cancer Res* 2003;63:7497-506.
20
21
- 22
23 [3] Palmer DH, Mautner V, Mirza D, Oliff S, Gerritsen W, Van Der Sijp JR, et al. Virus-
24
25 directed enzyme prodrug therapy: intratumoral administration of a replication-
26
27 deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. *J*
28
29 *Clin Oncol* 2004;22:1546-52.
30
31
32
- 33
34 [4] Braybrooke JP, Slade A, Deplanque G, Harrop R, Madhusudan S, Forster MD, et al.
35
36 Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients
37
38 with advanced breast cancer or melanoma. *Clin Cancer Res* 2005;11:1512-20.
39
40
41
- 42 [5] Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme
43
44 prodrug therapy of cancer. *Anticancer Drugs* 2005;16:349-59.
45
46
47
- 48 [6] Tai CK, Wang WJ, Chen TC, Kasahara N. Single-shot, multicycle suicide gene
49
50 therapy by replication-competent retrovirus vectors achieves long-term survival
51
52 benefit in experimental glioma. *Mol Ther* 2005;12:842-51.
53
54
- 55 [7] Niculescu-Duvaz I, Springer CJ. Introduction to the background, principles, and state
56
57 of the art in suicide gene therapy. *Mol Biotechnol* 2005;30:71-88.
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [8] Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. *J Pathol* 2006;208:299-318.
- [9] McNeish IA, Searle PF, Young LS, Kerr DJ. Gene directed enzyme prodrug therapy for cancer. *Advanced Drug Delivery Reviews* 1997;26:173-84.
- [10] Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes - paradigm for a prospective cancer control strategy. *Cancer Res* 1986;46:5276-81.
- [11] Mullen CA, Kilstrup M, Blaese RM. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. *Proc Natl Acad Sci USA* 1992;89:33-7.
- [12] McNeish IA, Green NK, Gilligan MG, Ford MJ, Mautner V, Young LS, et al. Virus directed enzyme prodrug therapy for ovarian and pancreatic cancer using retrovirally delivered *E. coli* nitroreductase and CB1954. *Gene Ther* 1998;5:1061-9.
- [13] Grove JJ, Searle PF, Weedon SJ, Green NK, McNeish IA, Kerr DJ. Virus directed enzyme prodrug therapy using CB1954. *Anti-Cancer Drug Design* 1999;14:461-72.
- [14] Weedon SJ, Green NK, McNeish IA, Gilligan MG, Mautner V, Wrighton CJ, et al. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of *E. coli* nitroreductase. *Int J Cancer* 2000;86:848-54.
- [15] Djeha AH, Thomson TA, Leung H, Searle PF, Young LS, Kerr DJ, et al. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors. *Mol Ther* 2001;3:233-40.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [16] Roberts JJ, Friedlos F, Knox RJ. CB1954 (2,4-dinitro-5-aziridinyl benzamide) becomes an interstrand crosslinking agent in Walker tumour cells. *Biochem Biophys Res Comm* 1986;140:1073-8.
- [17] Connors TA. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. *Gene Therapy* 1995;2:702-9.
- [18] Bridgewater JA, Springer CJ, Knox RJ, Minton NP, Michael NP, Collins MK. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. *Eur J Cancer* 1995;31A:2362-70.
- [19] de Poorter JJ, Tolboom TC, Rabelink MJ, Pieterman E, Hoeben RC, Nelissen RG, et al. Towards gene therapy in prosthesis loosening: efficient killing of interface cells by gene-directed enzyme prodrug therapy with nitroreductase and the prodrug CB1954. *J Gene Med* 2005;7:1421-8.
- [20] Drabek D, Guy J, Craig R, Grosveld F. The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954. *Gene Ther* 1997;4:93-100.
- [21] Gusterson BA, Cui W, Clark AJ. Development of novel selective cell ablation in the mammary gland and brain to study cell-cell interactions and chemoprevention. *Recent Results Cancer Res* 2003;163:31-45; discussion 264-6.
- [22] Kwak SP, Malberg JE, Howland DS, Cheng KY, Su J, She Y, et al. Ablation of central nervous system progenitor cells in transgenic rats using bacterial nitroreductase system. *J Neurosci Res* 2007;85:1183-93.
- [23] Pisharath H, Parsons MJ. Nitroreductase-mediated cell ablation in transgenic zebrafish embryos. *Methods Mol Biol* 2009;546:133-43.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [24] Smits AM, van den Hengel LG, van den Brink S, Metz CH, Doevendans PA, Goumans MJ. A new in vitro model for stem cell differentiation and interaction. *Stem Cell Res* 2009;2:108-12.
- [25] Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells. *Nat Med* 1997;3:1354-61.
- [26] Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. *Hum Gene Ther* 1999;10:1239-49.
- [27] Freytag SO, Khil M, Stricker H, Peabody J, Menon M, DePeralta-Venturina M, et al. Phase I Study of Replication-competent Adenovirus-mediated Double Suicide Gene Therapy for the Treatment of Locally Recurrent Prostate Cancer. *Cancer Res* 2002;62:4968-76.
- [28] Patel P, Young JG, Mautner V, Ashdown D, Bonney S, Pineda RG, et al. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954. *Mol Ther* 2009;17:1292-9.
- [29] Green NK, McNeish IA, Doshi R, Searle PF, Kerr DJ, Young LS. Immune enhancement of nitroreductase-induced cytotoxicity: Studies using a bicistronic adenovirus vector. *Int J Cancer* 2003;104:104-12.
- [30] Chen MJ, Green NK, Reynolds GM, Flavell JR, Mautner V, Kerr DJ, et al. Enhanced efficacy of *Escherichia coli* nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector. *Gene Ther* 2004;11:1126-36.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [31] Lukashev AN, Fuerer C, Chen MJ, Searle P, Iggo R. Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954. *Hum Gene Ther* 2005;16:1473-83.
- [32] Grove JI, Lovering AL, Guise C, Race PR, Wrighton CJ, White SA, et al. Generation of *Escherichia coli* nitroreductase mutants conferring improved cell sensitization to the prodrug CB1954. *Cancer Res* 2003;63:5532-7.
- [33] Guise CP, Grove JI, Hyde EI, Searle PF. Direct positive selection for improved nitroreductase variants using SOS triggering of bacteriophage lambda lytic cycle. *Gene Ther* 2007;14:690-8.
- [34] Anlezark GM, Melton RG, Sherwood RF, Coles B, Friedlos F, Knox RJ. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)--I. Purification and properties of a nitroreductase enzyme from *Escherichia coli*--a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). *Biochem Pharmacol* 1992;44:2289-95.
- [35] Jarrom D, Jaberipour M, Guise CP, Daff S, White SA, Searle PF, et al. Steady-state and stopped-flow kinetic studies of three *Escherichia coli* NfsB mutants with enhanced activity for the prodrug CB1954. *Biochemistry* 2009. Epub date 2009/07/08, doi 10.1021/bi900674m
- [36] Workman P, White RAS, Talbot K. CB1954 revisited. I. Disposition kinetics and metabolism. *Cancer Chemother Pharmacol* 1986;16:1-8.
- [37] Chung-Faye G, Palmer D, Anderson D, Clark J, Downes M, Baddeley J, et al. Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954. *Clin Cancer Res* 2001;7:2662-8.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [38] Lovering AL, Hyde EI, Searle PF, White SA. The structure of *Escherichia coli* nitroreductase complexed with nicotinic acid: three crystal forms at 1.7Å, 1.8Å and 2.4Å resolution. *J Mol Biol* 2001;309:203-13.
- [39] Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* 1976;72:248-54.
- [40] Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *Journal of General Virology* 1977;36:59-72.
- [41] Fallaux FJ, Kranenburg O, Cramer SJ, Houweling A, van Ormondt H, Hoeben RC, et al. Characterization of 911: a new helper cell line for the titration and propagation of early-region-1-deleted adenoviral vectors. *Human Gene Therapy* 1996;7:215-22.
- [42] Jiang Y, Han J, Yu C, Vass SO, Searle PF, Browne P, et al. Design, synthesis, and biological evaluation of cyclic and acyclic nitrobenzylphosphoramidate mustards for *E. coli* nitroreductase activation. *J Med Chem* 2006;49:4333-43.
- [43] Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J Immunol Methods* 1983;65:55-63.
- [44] Green NK, Youngs DJ, Neoptolemos JP, Friedlos F, Knox RJ, Springer CJ, et al. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the *E. coli* nitroreductase gene. *Cancer Gene Therapy* 1997;4:229-38.
- [45] Cosset FL, Takeuchi Y, Battini JL, Weiss RA, Collins MK. High-titer packaging cells producing recombinant retroviruses resistant to human serum. *J Virol* 1995;69:7430-6.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [46] Parkinson GN, Skelly JV, Neidle S. Crystal structure of FMN-dependent nitroreductase from *Escherichia coli* B: A prodrug-activating Enzyme. *J Med Chem* 2000;43:3624-31.
- [47] Anlezark GM, Melton RG, Sherwood RF, Wilson WR, Denny WA, Palmer BD, et al. Bioactivation of dinitrobenzamide mustards by an *E. coli* B nitroreductase. *Biochem Pharmacol* 1995;50:609-18.
- [48] Yoshikuni Y, Ferrin TE, Keasling JD. Designed divergent evolution of enzyme function. *Nature* 2006;440:1078-82.
- [49] Wilson WR, Pullen SM, Hogg A, Helsby NA, Hicks KO, Denny WA. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. *Cancer Res* 2002;62:1425-32.
- [50] Helsby NA, Ferry DM, Patterson AV, Pullen SM, Wilson WR. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. *Br J Cancer* 2004;90:1084-92.
- [51] Singleton DC, Li D, Bai SY, Syddall SP, Smaill JB, Shen Y, et al. The nitroreductase prodrug SN 28343 enhances the potency of systemically administered armed oncolytic adenovirus ONYX-411(NTR). *Cancer Gene Ther* 2007;14:953-67.
- [52] Hu L, Yu C, Jiang Y, Han J, Li Z, Browne P, et al. Nitroaryl phosphoramides as novel prodrugs for *E. coli* nitroreductase activation in enzyme prodrug therapy. *J Med Chem* 2003;46:4818-21.
- [53] Kraulis PJ. MOLSCRIPT: A program to produce both detailed and schematic plots of protein structures. *Journal of Applied Crystallography* 1991;24:946-50.

Figure Legends

FIGURE 1

Active site amino acid residues of NTR mutated in this study. (A) Structure of the active site of NTR showing the tightly-bound FMN, substrate analogue nicotinic acid (NIC), and the amino acid residues mutated in this study [32]. Figure prepared using programmes MOLSCRIPT and POV-Ray [53]. (B) Matrix showing the single mutants used and the double mutants generated from these. ^a — combination not made; ^b — same residue; ^c — mutant represented elsewhere on matrix.

FIGURE 2

Assay of NTR mutants in *E. coli*. (A) Replica plating of *E. coli* expressing NTR mutants at a range of CB1954 concentrations. *E. coli* UT5600 lysogenised with the λ JG3J1 vector expressing different NTR mutants were grown overnight in liquid culture in 96-well plates, then replica-plated onto 9 cm agar plates containing the indicated concentrations of CB1954, as described previously [32]. The plates were photographed after overnight incubation at 37°C. Clones carrying the empty vector, WT NTR and a selection of mutants are indicated. (B) Colony-forming assay, showing the plating efficiency of selected mutants at different concentrations of CB1954. Curves were fitted using GraphPad Prism, and used to determine the IC₅₀s as listed in Table 2. (C) Western blot comparing the level of expression of the different NTR mutants in *E. coli* lysogens.

FIGURE 3

Sensitisation of SKOV3 cells to prodrugs by adenoviruses expressing selected NTR mutants. SKOV3 cells were infected with 100 iu/cell adenovirus vectors expressing the indicated

1 NTRs or EGFP. After 48 h the cultures were treated with prodrug at the indicated
2
3 concentrations for 4 h, and cell viability was determined by MTT assay 72 h after prodrug
4
5 addition. The prodrugs used were (A) CB1954; (B) SN23862; and (C) LH7; their chemical
6
7 structures are shown as insets on the graphs. Data points show mean (\pm SD) of triplicate wells,
8
9 and are normalised to 100% survival in the absence of prodrug. For clarity, not all the tested
10
11 mutants are shown; the fold change in IC_{50} s for all the tested mutants relative to WT NTR are
12
13 listed in Table 3.
14
15

16 17 18 **FIGURE 4**

19
20
21 Western blot comparing expression of the different NTR mutants in SKOV3 cells. β -tubulin
22
23 was monitored as a loading control.
24
25

26 27 28 **FIGURE 5**

29
30
31 Response to CB1954 of tumours stably expressing WT or T41L/N71S NTR. (A) Mean
32
33 volume (\pm SEM) of SKOV3-NTR_{WT} tumours. Four mice (two treated with CB1954, and 2
34
35 treated with vehicle as control) were culled because of weight loss or poor condition before
36
37 day 33 post-treatment and are excluded from analysis. (B) Mean volume (\pm SEM) of SKOV3-
38
39 NTR_{T41L/N71S} tumours. Two mice treated with CB1954 were culled due to weight loss or poor
40
41 condition before day 33 post-treatment and are excluded from analysis. (C) Kaplan-Meier
42
43 analysis of time interval between treatment, and reaching tumour volume of ≥ 500 mm³. (D)
44
45 Western blot comparing level of NTR expression in SKOV3-NTR_{WT} and SKOV3-
46
47 NTR_{T41L/N71S} cells; the parental SKOV3 cells do not express NTR. The same blots were also
48
49 probed for β -tubulin expression as a loading control.
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

FIGURE 6

1
2
3
4 Effects of adenovirus-mediated expression of WT or T41L/N71S NTR, \pm CB1954, on growth
5
6 of PC3 tumours. PC3 human prostate carcinoma cells were mock-infected, or infected *in vitro*
7
8 with adenoviruses expressing WT or T41L/N71S NTR, then injected subcutaneously in
9
10 NOD-SCID mice. Mice were treated with CB1954 (30 mg/kg) or vehicle on the second and
11
12 third days following tumour seeding. Lines plot mean tumour volume (\pm SEM) for each
13
14 treatment group, until the first animal in the group was culled because of tumour size or
15
16 ulceration. Four mice in the CB1954 treatment groups (one with uninfected cells, one with
17
18 WT NTR and two with T41L/N71S NTR-treated tumours) were culled because of weight loss
19
20
21 within 7 days of prodrug treatment, and are excluded from further analysis.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1. Sensitivity to CB1954 of *E. coli* lysogens expressing NTR variants in replica plating assay.

Concentration of CB1954 ¹				
20 μ M	30 μ M	45 μ M	90 μ M	180 μ M
F124N		T41L F70V N71S F124H F124K F124M F124Q F124S F124W	WT S40A Y68G F70A	Empty vector S40G
S40A / F124K	T41L / F70A	S40A / T41L	S40A / N71S	S40G / Y68G
S40A / F124M		S40A / Y68G	T41L / F124K	S40G / F70A
S40A / F124N		S40A / F70A	T41L / F124Q	S40G / N71S
T41L / N71S		S40A / F124H	Y68G / F124H	S40A / F124S
N71S / F124K		S40A / F124Q	Y68G / F124Q	S40G / F124H
N71S / F124N		S40A / F124W	Y68G / F124S	S40G / F124K
		S40G / F124M	F70A / N71S	S40G / F124N
		T41L / Y68G	F70V / F124K	S40G / F124Q
		T41L / F124H	F70V / F124Q	S40G / F124S
		T41L / F124M	F70V / F124S	S40G / F124W
		T41L / F124N	F70V / F124W	Y68G / F124N
		T41L / F124S	N71S / F124M	
		T41L / F124W		
		Y68G / F124K		
		Y68G / F124M		
		Y68G / F124W		
		F70V / F124H		
		F70V / F124M		
		F70V / F124N		
		N71S / F124H		
		N71S / F124Q		
		N71S / F124S		
		N71S / F124W		

¹ Highest tested concentration of prodrug CB1954 at which *E. coli* lysogens carrying the empty vector, or expressing the indicated nitroreductase genes, were able to grow.

Table 2

Sensitivity to CB1954 of *E. coli* lysogens expressing NTR variants, determined by colony forming efficiency

Nitroreductase	IC ₅₀ (μM CB1954) ¹	Improvement over WT ²
WT	145 ± 3.5	1
F124K	25.8 ± 0.7	5.6
F124N	18.3 ± 1.4	7.9
S40A / F124K	15.0 ± 0.5	9.7
S40A / F124M	17.2 ± 1.7	8.4
S40A / F124N	16.3 ± 1.1	8.9
T41L / F70A	20.4 ± 0.6	7.1
T41L / N71S	11.4 ± 1.2	12.7
N71S / F124K	14.9 ± 0.5	9.7
N71S / F124N	14.5 ± 0.6	10.0

¹ prodrug concentration giving 50% reduction in plating efficiency, determined by fitting a sigmoid curve to the data, ± standard error

² fold reduction in IC₅₀ relative to WT NTR


Table 3

Fold reduction in IC₅₀ of prodrugs CB1954, SN23862 and LH7, for SKOV3 cells infected with adenoviruses expressing NTR variants, relative to WT NTR

NTR ¹	Fold reduction in IC ₅₀ ²		
	CB1954	SN23862	LH7
WT	1.00	1.00	1.00
F124K	4.08 ± 0.19	1.55 ± 0.21	0.15 ± 0.04
F124N	5.66 ± 1.83	1.07 ± 0.38	0.13 ± 0.06
T41L	5.31 ± 0.88	1.92 ± 0.13	0.51 ± 0.08
S40A/F124K	5.08 ± 1.91	1.95 ± 0.18	0.18 ± 0.02
S40A/F124M	9.76 ± 0.65	3.70 ± 0.61	1.68 ± 0.11
S40A/F124N	3.38 ± 1.14	0.91 ± 0.42	0.09 ± 0.05
T41L/F70A	17.20 ± 2.90	4.83 ± 0.31	0.49 ± 0.13
T41L/N71S	14.35 ± 1.86	1.57 ± 0.37	0.91 ± 0.12
N71S/F124K	0.09 ± 0.03	<0.01	0.03 ± 0.01
N71S/F124N	0.14 ± 0.02	<0.01	<0.01




¹ SKOV3 cells were infected with adenovirus vectors expressing either WT NTR, or the indicated single or double NTR mutants, at a moi of 100 iu/cell


² Fold reduction in IC₅₀ relative to WT NTR, ± SD for 3 experiments using CB1954, or 2 experiments with SN23862 and LH7.




(B)


		First substitution					
		S40A	S40G	T41L	Y68G	F70V	N71S
Second substitution	T41L	✓	— ^a	— ^b	— ^c	— ^a	— ^c
	Y68G	✓	✓	✓	— ^b	— ^a	— ^a
	F70A	✓	✓	✓	— ^a	— ^b	✓
	N71S	✓	✓	✓	— ^a	— ^a	— ^b
	F124H	✓	✓	✓	✓	✓	✓
	F124K	✓	✓	✓	✓	✓	✓
	F124M	✓	✓	✓	✓	✓	✓
	F124N	✓	✓	✓	✓	✓	✓
	F124Q	✓	✓	✓	✓	✓	✓
	F124S	✓	✓	✓	✓	✓	✓
F124W	✓	✓	✓	✓	✓	✓	






Accepted Manuscript







Improving prodrug activation gene therapy for cancer by enzyme engineering for better prodrug activation.

